Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This study is ongoing, but not recruiting participants.
Study NCT01518309 Information provided by ACADIA Pharmaceuticals Inc.
First Received on December 16, 2008. Last Updated on January 25, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease Psychosis
Additional conditions recognized in this trial
More general conditions related to this trial
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
pimavanserin tartrate (ACP-103)
Sponsors listed in this trial
ACADIA Pharmaceuticals Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers